Preferences help
enabled [disable] Abstract
Number of results
2014 | 68 | 6 | 415–423
Article title

Polimorfizm -643C/T genu RANKL i jego związek z osteoporozą u kobiet po menopauzie

Title variants
-643C/T polymorphism of RANKL gene and its association with osteoporosis in postmenopausal women
Languages of publication
INTRODUCTION RANKL is a key cytokine involved in osteoclast differentiation from its precursors, activation and survival of osteoclasts themselves. Because RANKL binds with RANK, the presence of RANK on target cells is a necessary condition of target cell control mediated by RANKL. AIM OF STUDY The aim of the study was to examine the incidence of RANKL gene polymorphism and evaluate its association with the clinical parameters concerning bone turnover and the degree of postmenopausal osteoporosis development. MATERIAL AND METHODS The study was conducted among a group of 570 women at postmenopausal age (404) and reproductive age (166). The group at postmenopausal age included women with osteoporosis, osteopenia as well as healthy individuals. The women at reproductive age were healthy. The polymorphism incidence of the examined gene in a group of patients with determined bone mineral density (BMD) and in the control group was studied. The study was performed by means of the RFLP-PCR method. RESULTS The obtained results did not show a correlation of RANKL gene C-643T polymorphism with decreased bone density or increased risk of osteoporotic changes after menopause. CONCLUSIONS The homozygote of the TT polymorphism of the RANKL receptor gene seems to be an increased risk factor of osteoporosis development and is associated with growth and birth mass.
WSTĘP RANKL jest kluczową cytokiną uczestniczącą w różnicowaniu osteoklastu ze swoich prekursorów oraz aktywacji i przeżyciu samych osteoklastów. Ponieważ wiąże się z RANK, obecność RANK na komórkach docelowych jest nieodzownym warunkiem kontroli komórek docelowych za pośrednictwem RANKL. CEL PRACY Celem pracy było zbadanie częstości występowania polimorfizmu genu RANKL oraz ocena jego związku z parametrami klinicznymi dotyczącymi obrotu kostnego i stopnia zaawansowania osteoporozy pomenopauzalnej. MATERIAŁY I METODY Badania przeprowadzono w grupie 570 kobiet w wieku postmenopauzalnym (404 kobiety) i rozrodczym (166 kobiet). Grupa w wieku postmenopauzalnym obejmowała kobiety z osteoporozą, osteopenią i zdrowe. Kobiety w wieku rozrodczym były zdrowe. Zbadano częstość występowania polimorfizmu badanego genu w grupie pacjentek z oznaczoną gęstością mineralną kości (bone mineral density – BMD) oraz w grupie kontrolnej. Badanie przeprowadzono metodą RFLP-PCR. WYNIKI Uzyskane wyniki badań nie wykazały korelacji polimorfizmu C-643T genu RANKL ze zmniejszoną gęstością kości oraz zwiększonym ryzykiem występowania zmian osteoporotycznych po menopauzie. WNIOSKI Wydaje się, że homozygota TT polimorfizmu genu receptora RANKL może być czynnikiem zwiększonego ryzyka wystąpienia osteoporozy i jest powiązana ze wzrostem i masą urodzeniową.
Physical description
  • 1. Ralston S.H. Genetics of osteoporosis. Proc. Nutr. Soc. 2007; 66: 158–165.
  • 2. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003; 111: 1221–1230.
  • 3. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 1999; 256: 449–455.
  • 4. Lacey D.L., Tan H.L., Lu J., Kaufman S. et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 2000; 157: 435–448.
  • 5. Chen X.W., Garner S.C., Anderson J.J. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem. Biophys. Res. Commun. 2002; 295: 417–422.
  • 6. Bord S., Ireland D.C., Beavan S.R., Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32: 136–141.
  • 7. Fleurence R.L., Iglesias C.P., Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007; 25: 913–933.
  • 8. Boonen S., McClung M.R., Eastell R., El-Hajj Fuleihan G., Barton I.P., Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J. Am. Geriatr. Soc. 2004; 52: 1832–1839.
  • 9. Fili S., Karalaki M., Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int. 2009; 12: 9–26.
  • 10. Brown J.M., Zhang J., Keller E.T. OPG, RANKL, and RANK in cancer metastasis: Expression and regulation. Cancer Treat. Res. 2004; 118: 149–172.
  • 11. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor B ligand and their differential expression in bone and thymus. Endocrinology 2001; 142: 1419–1426.
  • 12. Suzuki J., Ikeda T., Kuroyama H. et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem. Biophys. Res. Commun. 2004; 314: 1021–1027.
  • 13. Ikeda T., Kasai M., Suzuki J. et al. Multimerization of the receptor activator of nuclear factor-B ligand (RANKL) isoforms and regulation of osteoclastogenesis. J. Biol. Chem. 2003; 278: 47217–47222.
  • 14. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 2005; 57: 389–395.
  • 15. Blair J.M., Zhou H., Seibel M.J., Dunstan C.R. Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 2006; 3: 41–49.
  • 16. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 2005; 115: 3318–3325.
  • 17. Robbins J.A., Schott A.M., Garnero P., Delmas P.D., Hans D., Meunier P.J. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos. Int. 2005; 16: 149–154.
  • 18. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif. Tissue. Int. 2003; 73: 423–432.
  • 19. Lyritis G.P., Georgoulas T., Zafeiris C.P. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann. NY Acad. Sci. 2010; 1205: 277–283.
  • 20. Hodge J.M., Kirkland M.A., Nicholson G.C. Multiple roles of M-CSF in human osteoclastogenesis. J. Cell. Biochem. 2007; 102: 759–768.
  • 21. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141: 4768–4776.
  • 22. Mencej S., Albagha O.M., Prezelj J., Kocjan T., Marc J. Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. Mol. Endocrinol. 2008; 40: 273–279.
  • 23. Mencej S., Prezelj J., Kocijancic A., Ostanek B., Marc J. Association of NFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. Maturitas 2006; 55: 219–226.
  • 24. Takacs I., Lazary A., Kosa J.P. et al. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression. Eur. J. Endocrinol. 2010; 162: 423–431.
  • 25. Mencej-Bedrac S., Prezelj J., Kocjan T. et al. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J. Mol. Endocrinol. 2009; 42: 239–247.
  • 26. Dong S.S., Liu X.G., Chen Y. et al. Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. Calcif. Tissue Int. 2009; 85: 104–112.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.